COPD
-
For the neuromuscular disease community, ventilation coverage victory doesn’t carry over
Patient advocate Spero Koulouras said he believes CMS home ventilation coverage criteria for patients with disorders such as ALS are still ambiguous enough that private insurers have interpreted them to deny and delay coverage.
-
MATINEE shows positive results for mepolizumab in COPD
Experts Frank Sciurba, MD, FCCP, and Gerard J. Criner, MD, FCCP, said clinicians have a second option for treating patients with high type 2 inflammation now that the FDA has approved the drug for those with an eosinophilic phenotype.
-
Tezepelumab trial demonstrates solid results for treatment of CRSwNP
Joseph K. Han, MD, said the data showed the highest change in sinonasal outcome test scores from baseline compared with any other biologic studies for chronic rhinosinusitis with nasal polyps.
-
COPD: Could there be a GLP-1 for that?
While real-world data are promising, experts Dinah Foer, MD, and William B. Feldman, MD, say more randomized controlled trials are needed to confirm whether antihyperglycemic medications can improve respiratory outcomes in patients with comorbid type 2 diabetes and COPD.
-
A sticky road: Mucus pathology in COPD
Targeting mucus pathology could fulfill an unmet therapeutic need in managing patients with COPD and provide a novel approach to addressing the underlying mechanisms contributing to airway obstruction.
-
COPD program aims to close gaps in diagnosis and treatment
CHEST’s new Bridging Specialties®: Timely Diagnosis and Treatment for COPD program is focused on enhancing collaboration between PCPs and pulmonologists.
-
Study demonstrates viability of biologics for severe asthma, COPD exacerbations in eosinophilic inflammation
While larger studies are needed, Dharani K. Narendra, MD, FCCP, said the findings from the ABRA trial could be a game changer and reduce the need for glucocorticoids for some patients.
-
FDA grants clearance for SIMEOX 200 for patients with chronic lung disease
The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.
-
Updated GOLD report includes significant clinical implications for COPD management
Gerard J. Criner, MD, FCCP, a member of the GOLD science committee, said one notable change was the adoption of race-neutral algorithms and equations in predictive values for lung function testing and measuring lung impairment.
-
Consequences of wildfire smoke exposure extend beyond local area
In a recent study, Mary E. Maldarelli, MD, and colleagues demonstrated that wildfires can increase health risks even from thousands of miles away.
